Evidence map›Paper›PMID 24498161›Full record

ArticlePloS one2014

Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat.

Xiang Shan Ren, Yasunori Sato, Kenichi Harada, Motoko Sasaki, Shinichi Furubo, Jing Yu Song, Yasuni Nakanuma

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Small Molecules Targeting Programmed Cell Death in Breast Cancer Cells.International journal of molecular sciences · 2021
    Review
  5. Molecular Pathophysiology of Autosomal Recessive Polycystic Kidney Disease.International journal of molecular sciences · 2021
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Observational
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Xiang Shan RenDepartment of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan ; Department of Pathology, Yanbian University College of Medicine, Yanji-city, China.
Yasunori SatoDepartment of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Kenichi HaradaDepartment of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Motoko SasakiDepartment of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Shinichi FuruboDepartment of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Jing Yu SongDepartment of Pathology, Yanbian University College of Medicine, Yanji-city, China.
Yasuni NakanumaDepartment of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan ; Department of Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Kanazawa University · JPShizuoka Cancer Center · JPYanbian University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The polycystic kidney (PCK) rat is an animal model of Caroli's disease as well as autosomal recessive polycystic kidney disease (ARPKD). The signaling pathways involving the mammalian target of rapamycin (mTOR) are aberrantly activated in ARPKD. This study investigated the effects of inhibitors for the cell signaling pathways including mTOR on cholangiocyte proliferation of the PCK rat. Cultured PCK cholangiocytes were treated with rapamycin and everolimus [inhibitors of mTOR complex 1 (mTOC1)], LY294002 [an inhibitor of phosphatidylinositol 3-kinase (PI3K)] and NVP-BEZ235 (an inhibitor of PI3K and mTORC1/2), and the cell proliferative activity was determined in relation to autophagy and apoptosis. The expression of phosphorylated (p)-mTOR, p-Akt, and PI3K was increased in PCK cholangiocytes compared to normal cholangiocytes. All inhibitors significantly inhibited the cell proliferative activity of PCK cholangiocytes, where NVP-BEZ235 had the most prominent effect. NVP-BEZ235, but not rapamycin and everolimus, further inhibited biliary cyst formation in the three-dimensional cell culture system. Rapamycin and everolimus induced apoptosis in PCK cholangiocytes, whereas NVP-BEZ235 inhibited cholangiocyte apoptosis. Notably, the autophagic response was significantly induced following the treatment with NVP-BEZ235, but not rapamycin and everolimus. Inhibition of autophagy using siRNA against protein-light chain3 and 3-methyladenine significantly increased the cell proliferative activity of PCK cholangiocytes treated with NVP-BEZ235. In vivo, treatment of the PCK rat with NVP-BEZ235 attenuated cystic dilatation of the intrahepatic bile ducts, whereas renal cyst development was unaffected. These results suggest that the aberrant activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat, and inhibition of the pathway can reduce cholangiocyte proliferation via the mechanism involving apoptosis and/or autophagy.

Indexed as

AnimalsApoptosisAutophagyCell ProliferationCells, CulturedPhosphatidylinositol 3-KinasePolycystic Kidney DiseasesRatsSignal TransductionTOR Serine-Threonine KinasesmTOR protein, ratPhosphatidylinositol 3-KinaseTOR Serine-Threonine Kinases

Identifiers

PMID24498161
PMCPMC3907540
OpenAlexW2007412632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.